ethyl 2-(benzylideneamino)-2-ethylhexanoate | 152802-64-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ethyl 2-(benzylideneamino)-2-ethylhexanoate
• 英文别名: Ethyl 2-benzylideneamino-2-ethylhexanoate
• CAS: 152802-64-7
• 化学式: C₁₇H₂₅NO₂
• 分子量: 275.391
• InChiKey: KNCUZLUTDGZALS-UHFFFAOYSA-N

物化性质

• 沸点：
  360.8±25.0 °C(Predicted)
• 密度：
  0.95±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  20
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  38.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 2-(benzylideneamino)-2-ethylhexanoate 在 盐酸 作用下， 反应 1.0h， 以94%的产率得到2-氨基-2-乙基己酸乙酯
  参考文献：
  名称：

  Liu, Weiguo; Ray, Paul; Benezra, Steven A., Journal of the Chemical Society. Perkin transactions I, 1995, # 5, p. 553 - 560

  摘要：

  DOI：
• 作为产物：
  描述：

  2-氨基丁酸乙酯盐酸盐 在 三乙胺 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 10.0h， 生成 ethyl 2-(benzylideneamino)-2-ethylhexanoate
  参考文献：
  名称：

  Liu, Weiguo; Ray, Paul; Benezra, Steven A., Journal of the Chemical Society. Perkin transactions I, 1995, # 5, p. 553 - 560

  摘要：

  DOI：

文献信息

• Hypolipidaemic benzothiazepine compounds
  申请人：Glaxo Wellcome Inc.

  公开号：US05663165A1

  公开（公告）日：1997-09-02

  The present invention is directed to the following compounds of formula (I): ##STR1## wherein l is an integer of from 0 to 4; m is an integer of from 0 to 5; n is an integer of from 0 to 2; R and R' are atoms or groups independently selected from halogen, nitro, phenylalkoxy, C.sub.1-4 alkoxy, C.sub.1-6 alkyl and --O(CH.sub.2).sub.p SO.sub.3 R" wherein p is an integer of from 1 to 4 and R" is hydrogen or C.sub.1-6 alkyl, wherein said phenylalkoxy, alkoxy and alkyl groups are optionally substituted by one or more halogen atoms; R.sup.4 is a C.sub.1-6 straight alkyl group; and R.sup.5 is a C.sub.2-6 straight alkyl group; and their salts, solvates and physiologically functional derivatives, with processes and novel intermediates for their preparation, with pharmaceutical compositions containing them and with their use in medicine, particularly in the prophylaxis and treatment of hyperlipidaemic conditions, such as atherosclerosis.

  本发明涉及以下式(I)的化合物：##STR1## 其中l为0至4的整数；m为0至5的整数；n为0至2的整数；R和R'是原子或独立选择自卤素、硝基、苯基烷氧基、C.sub.1-4烷氧基、C.sub.1-6烷基和--O(CH.sub.2).sub.p SO.sub.3R"的基团，其中p为1至4的整数，R"为氢或C.sub.1-6烷基，其中所述的苯基烷氧基、烷氧基和烷基基团可以被一个或多个卤素原子取代；R.sup.4是C.sub.1-6直链烷基；R.sup.5是C.sub.2-6直链烷基；以及它们的盐、溶剂化物和生理功能衍生物，以及用于它们的制备的过程和新的中间体，含它们的制药组合物和在医学上的使用，特别是在预防和治疗高脂血症状况，如动脉硬化方面的使用。
• Hypolipidaemic condensed 1,4-thiazepines
  申请人：Glaxo Wellcome Inc.

  公开号：US05817652A1

  公开（公告）日：1998-10-06

  The invention provides a compound of formula (I), wherein n is an integer of from 0 to 2; R is an optional substituent; R.sup.1 is hydrogen or C.sub.1-6 alkyl; R.sup.2 is an atom or group selected from hydrogen, C.sub.1-4 alkyl (including cycloalkyl and cycloalkylalkyl), C.sub.1-4 alkoxy, pyrryl, thienyl, pyridyl, 1,3-benzodioxolo, phenyl and naphthyl, which groups are optionally substituted; R.sup.3 is hydrogen, OH, C.sub.1-6 alkyl, C.sub.1-6 alkoxy or --O C.sub.1-6 acyl; R.sup.4 is a group independently selected from C.sub.1-6 alkyl (including cycloalkyl and cycloalkylalkyl), C.sub.2-6 alkenyl, and C.sub.2-6 -alkynyl which groups are optionally substituted; R.sup.5 is a group independently selected from C.sub.2-6 alkyl (including cycloalkyl and cycloalkylalkyl), C.sub.2-6 alkenyl and C.sub.2-6 alkynyl, which groups are optionally substituted; or R.sup.4 and R.sup.5, together with the carbon atom to which they are attached, form a C.sub.3-7 spiro cycloalkyl group which is optionally substituted; R.sup.6 and R.sup.7 are independently selected from hydrogen and C.sub.1-6 alkyl; and X is an aromatic or non-aromatic monocyclic or bicyclic ring system having from 5 to 10 carbon atoms (including the two carbon atoms forming part of the thiazepine ring) wherein optionally one or more of the carbon atoms is/are replaced by heteroatom(s) independently selected from nitrogen, oxygen and sulphur, or X is an aromatic or non-aromatic monocyclic or bicyclic ring system having from 5 to 10 carbon atoms (including the two carbon atoms forming part of the thiazepine ring) wherein one or more of the carbon atoms is/are replaced by heteroatom(s) independently selected from nitrogen, oxygen and sulphur; and salts, solvates and physiologically functional derivatives thereof, pharmaceutical formulations comprising such compounds, processes for their preparation and their use in reducing bile acid uptake and hence as hypolipidaemic compounds. ##STR1##

  本发明提供了一种化合物，其化学式为（I），其中n是0到2的整数；R是可选的取代基；R.sup.1是氢或C.sub.1-6烷基；R.sup.2是从氢，C.sub.1-4烷基（包括环烷基和环烷基烷基），C.sub.1-4烷氧基，吡咯基，噻吩基，吡啶基，1,3-苯并二氧杂环，苯基和萘基中选择的原子或基团，这些基团可以被取代；R.sup.3是氢，OH，C.sub.1-6烷基，C.sub.1-6烷氧基或--O C.sub.1-6酰基；R.sup.4是从C.sub.1-6烷基（包括环烷基和环烷基烷基），C.sub.2-6烯基和C.sub.2-6-炔基中独立选择的基团，这些基团可以被取代；R.sup.5是从C.sub.2-6烷基（包括环烷基和环烷基烷基），C.sub.2-6烯基和C.sub.2-6炔基中独立选择的基团，这些基团可以被取代；或R.sup.4和R.sup.5与它们连接的碳原子一起形成一个C.sub.3-7螺环烷基团，该基团可以被取代；R.sup.6和R.sup.7独立选择自氢和C.sub.1-6烷基；X是具有5到10个碳原子（包括构成噻唑环一部分的两个碳原子）的芳香或非芳香单环或双环环系，其中可选地一个或多个碳原子被氮，氧和硫独立选择的杂原子替换，或者X是具有从5到10个碳原子（包括构成噻唑环一部分的两个碳原子）的芳香或非芳香单环或双环环系，其中一个或多个碳原子被氮，氧和硫独立选择的杂原子替换；以及这些化合物的盐，溶剂化合物和生理功能衍生物，包括这样的化合物的制药组合物，它们的制备过程以及它们在减少胆汁酸吸收和因此作为降脂化合物的用途。
• Hypolipidemic benzothiazepine compounds
  申请人：Glaxo Wellcome Inc.

  公开号：US05859240A1

  公开（公告）日：1999-01-12

  The present invention is concerned with processes for preparing hypolipidaemic benzothiazepine compounds of formula (I) ##STR1## wherein l is an integer of from 0 to 4; m is an integer of from 0 to 5; n is an integer of from 0 to 2; R and R' are atoms or groups independently selected from halogen, nitro, phenylalkoxy, C.sub.1-4 alkoxy, C.sub.1-6 alkyl and --O(CH.sub.2).sub.p SO.sub.3 R" wherein p is an integer of from 1 to 4 and R" is hydrogen or C.sub.1-6 alkyl, wherein said phenylalkoxy, alkoxy and alkyl groups are optionally substituted by one or more halogen atoms; R.sup.4 is C.sub.1-6 straight alkyl group; and R.sup.5 is a C.sub.2-6 straight alkyl group; and their salts, solvates and physiologically functional derivatives; and intermediates useful in said processes.

  本发明涉及制备具有下式（I）的降脂苯并噻吩化合物的过程：##STR1## 其中l为0至4的整数；m为0至5的整数；n为0至2的整数；R和R'是原子或独立选择自卤素，硝基，苯基烷氧基，C.sub.1-4烷氧基，C.sub.1-6烷基和--O(CH.sub.2).sub.p SO.sub.3 R"，其中p为1至4的整数，R"为氢或C.sub.1-6烷基，其中所述的苯基烷氧基，烷氧基和烷基可选择地被一个或多个卤素原子取代；R.sup.4是C.sub.1-6的直链烷基；R.sup.5是C.sub.2-6的直链烷基；以及它们的盐，溶剂化合物和生理功能衍生物；以及在所述过程中有用的中间体。
• Hypolipidemic 1,4-benzothiazepine-1,1-dioxides
  申请人：Glaxo Wellcome Inc.

  公开号：US05910494A1

  公开（公告）日：1999-06-08

  The invention is concerned with novel hypolipidemic compounds of formula (I), with processes and novel intermedites for their preparation, pharmaceutical compositions containing them and with their use in medicine, particularly in the prophylaxis and treatment of hyperlipidemic conditions, such as atherosclerosis. ##STR1##

  该发明涉及公式（I）的新型降脂化合物，以及制备它们的新型中间体和过程，包含它们的药物组合物以及它们在医学上的应用，特别是在预防和治疗高脂血症等高脂血症情况，如动脉硬化方面的应用。 ##STR1##
• Liu, Weiguo; Ray, Paul; Benezra, Steven A., Journal of the Chemical Society. Perkin transactions I, 1995, # 5, p. 553 - 560
  作者：Liu, Weiguo、Ray, Paul、Benezra, Steven A.

  DOI：——

  日期：——